Exicure, Inc. (Nasdaq: XCUR), plunged -9.52% to $1.9 in the premarket session after a pharmaceutical leader in novel biopharmaceuticals incorporating spherical nucleic acids, today announced that U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the ‘251 patent) and No. 10,837,018 (the ‘018 patent), and allowed U.S. patent application 14/907,430 (the ‘430 application), further strengthening the Company’s patent portfolio and coverage for cavrotolimod.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
The ‘018 patent and the’ 430 application, all entitled,’ Spherical Nucleic Acid-based Structures as Prophylactic and Therapeutic Immunostimulatory Agents,’ cover nanoparticles a corona of CpG oligonucleotides and their cancer therapy techniques.
Read More
The ‘251 patent, jointly held by the Company and Northwestern University, is guided to liposomal nanoparticles with toll-like receptor 9 (TLR9) agonist oligonucleotides and cancer treatment methods, entitled,’ Liposomal Particles, Methods of Producing Same and Uses Thereof.’
